Hanmi Pharmaceutical: Hanmi Pharmaceutical: Epeglenatide auto-injector wins MFDS approval
AI reading
★★★★ Bullish · Material event
Epeglenatide auto-injector receives MFDS marketing authorization
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
🤖 10/7 Why the stock moved
Hanmi Pharmaceutical rallies on MFDS approval for GLP-1 obesity drug Epeoto Injector.
Hanmi Pharmaceutical gains as FDA-equivalent approval for Epeoto Injector bolsters its competitive edge in the high-demand GLP-1 obesity market, fueled by strong retail buying.
Other filings by Hanmi Pharmaceutical
- 10.02 ★★ Report on major shareholding
- 09.29 ★★ Files report on major shareholding
- 09.08 ★★ Files report on major shareholding
- 08.26 ★★ Hanmi Pharmaceutical signs licensing deal for AML drug HM43239
- 08.24 ★★★★★ Signs HM17321 licensing deal and receives major upfront payment
- 08.21 ★★ Amended disclosure regarding material business decision
For information only. Not investment advice.